[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351396-105":59,"doc-detail-351396-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","small-cell-lung-cancer-classification-unraveling-heterogeneity-to-enable-personalized-treatments","Small Cell Lung Cancer Classification - Unraveling Heterogeneity to Enable Personalized Treatments","","Small cell lung cancer (SCLC) is an aggressive, fast-growing thoracic malignancy with early metastatic spread and consistently poor survival outcomes. Recent advances highlight a heterogeneous molecular landscape in human tumors and preclinical models, prompting efforts to stratify SCLC into biologically distinct subgroups. This review summarizes classification attempts from the past decade, compares nomenclature across studies, and analyzes biological drivers such as transcription factors and the tumor immune microenvironment. It evaluates implications for subtype composition and plasticity, and outlines directions for personalized clinical trial design.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/small-cell-lung-cancer-classification-unraveling-heterogeneity-to-enable-personalized-treatments/351396/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/small-cell-lung-cancer-classification-unraveling-heterogeneity-to-enable-personalized-treatments/351396.png","ImageObject",300,407,{"name":92,"@type":93},"Aria Callaghan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":8},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is small cell lung cancer (SCLC) difficult to treat?","Question",{"text":112,"@type":113},"SCLC is an aggressive disease with rapid proliferation and early metastatic spread. Survival outcomes remain poor, and patients frequently relapse due to acquired resistance after initial treatment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What motivates classifying SCLC into subgroups?",{"text":117,"@type":113},"Research indicates that SCLC has a heterogeneous molecular profile, with differences in transcription factor expression and the tumor immune microenvironment. Subgrouping can reveal therapeutic vulnerabilities and support personalized clinical trial strategies.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the review approach classification attempts?",{"text":121,"@type":113},"The review summarizes impactful classification attempts from the past 10 years and highlights discrepancies and connections between study nomenclature. It also discusses biological factors that influence subtype composition and plasticity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351396,1790162107,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":8,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41},962084926284,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Small Cell Lung Cancer Classification: Unraveling Heterogeneity to Enable Personalized Treatments  \nKristiina Boettiger1, Ildik Kovcs2, Lilla Horvath2,3, Bsra Ernhofer1, Karin Schelch1, Maria Dorothea Pozonec2,3, Vivien Teglas2,3, Clemens Aigner1, Evelyn Megyesfalvi3,4,  \nFerenc Rnyi-Vmos2,3,5, Krisztina Bogos2, Christian Lang1,6, Abigail J. Deloria1, Carl M. Gay7, Lauren A. Byers7, Julien Sage8,9, Fred R. Hirsch10,11, Zsolt Megyesfalvi1,2,3, and Balazs Dome1,2,3,12  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Small cell lung cancer (SCLC) is an aggressive thoracic disease characterized by rapid proliferation and early metastatic spread. The survival outcomes for patients with SCLC remain notoriously poor, underlining that only modest improvements have been achieved in clinical settings to date. However, insights gained from human tumors and preclinical models in recent years have shed light on the heterogeneous molecular profile of SCLC. Numerous research groups have, therefore, begun to stratify SCLC into subgroups based on differential transcription factor expression, the tumor immune microenvironment, and other criteria. As SCLC\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | subtypes show major differences in their molecular landscape and biological behavior, they may offer unique therapeutic vulnerabilities and serve as a framework for future personalized clinical trials. Here, we summarize impactful classification attempts from the past 10 years, highlighting discrepancies and connections between the nomenclature of each study, and expound upon relevant factors of SCLC biology influencing subtype composition and plasticity. This review delves into the implications of subgrouping for understanding and treating SCLC, as well as potential future directions for SCLC research. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nSmall cell lung cancer (SCLC), constituting approximately 15% of all lung cancer cases, is highly associated with smoking and is characterized by rapid proliferation, increased vascularization, and aggressive behavior (1–3) . Due to early metastasis, most patients are diagnosed at extensive-stage (ES) disease, excluding surgical resection (4–6) .  \n1Department of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. 2National Koranyi Institute of Pulmonology, Budapest, Hungary. 3Department of Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary. 4Department of Thoracic and Abdominal Tumors and Clinical Pharmacology, National Institute of Oncology, Budapest, Hungary. 5National Institute of Oncology, National Tumor Biology Laboratory, Budapest, Hungary. 6Division of Pulmology, Department of Medicine II, Medical University of Vienna, Vienna, Austria. 7Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, ","cbCaisLpAdlGPpX1","https://ap.wps.com/l/cbCaisLpAdlGPpX1","pdf",4220531,12,"English","# Introduction\n## Disease burden and staging\n## Rationale for molecular classification\n# Treatment background and emerging approaches\n## Chemotherapy and resistance\n## Immunotherapy integration\n# Classification of SCLC heterogeneity\n## Transcription factor-driven subgroups\n## Immune microenvironment-based criteria\n# Implications and future directions\n## Personalized trial framework\n## Subtype plasticity considerations","[{\"question\":\"Why is small cell lung cancer (SCLC) difficult to treat?\",\"answer\":\"SCLC is an aggressive disease with rapid proliferation and early metastatic spread. Survival outcomes remain poor, and patients frequently relapse due to acquired resistance after initial treatment.\"},{\"question\":\"What motivates classifying SCLC into subgroups?\",\"answer\":\"Research indicates that SCLC has a heterogeneous molecular profile, with differences in transcription factor expression and the tumor immune microenvironment. Subgrouping can reveal therapeutic vulnerabilities and support personalized clinical trial strategies.\"},{\"question\":\"How does the review approach classification attempts?\",\"answer\":\"The review summarizes impactful classification attempts from the past 10 years and highlights discrepancies and connections between study nomenclature. It also discusses biological factors that influence subtype composition and plasticity.\"}]","Small Cell Lung Cancer Classification - Unraveling Heterogeneity to Enable Personalized Treatments | PDF",1790094002]